News

Public · Published

PRGO: Q3 margins weakened as impairments and operating pressures weighed on results; Infant Formula sale pending

Perrigo reported lower Q3 sales and gross margin and a net loss of $27.5M. Its nine-month operating loss included $335.9M in impairments. The company has an Infant Formula sale pending and expects a $275M–$375M held-for-sale loss in Q4.

Published:

Updated:

What happened

Perrigo reported lower Q3 sales and gross margin and a net loss of $27.5M. Its nine-month operating loss included $335.9M in impairments. The company has an Infant Formula sale pending and expects a $275M–$375M held-for-sale loss in Q4.

Confirmed

Global impact / market context

Lower sales and gross margin can reduce cash generated from each sale, while the reported losses and impairments point to additional pressure on results. The expected held-for-sale loss could further weigh on Q4 earnings; completing the sale may change the business and cash available, but no sale proceeds are stated.

Analyst inference

The article gives no share-price reaction, forecast comparisons, or details of the sale terms, so it does not establish how investors have priced the results. The key financial distinction is that impairments are recorded losses, while the pending sale and expected Q4 loss remain unresolved.

Analyst inference

What to watch

  1. Watch for confirmation that the Infant Formula sale closes, and for any stated timing or terms; the article says it is pending but gives no proceeds. Analyst inference
  2. Check whether Q4 results record the expected $275M–$375M held-for-sale loss, and how that accounting charge affects reported earnings for the quarter. Analyst inference
  3. Compare later sales and gross margin with Q3 levels to see whether operating pressure continues to reduce revenue and profit earned on each sale. Analyst inference

Evidence

  • Original source link unavailable